- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Loading...
Glenmark Life Sciences, a subsidiary of Glenmark Pharmaceuticals Ltd, is one of the leading developers and manufacturers of select high-value Active Pharmaceutical Ingredients. The company further operates in Contract Development and manufacturing operations to offer services to specialty Pharmaceutical companies.
Alivus Life Sciences acquired 76% of IQGenX Pharma for INR 9.12 Cr. This expands Alivus's capabilities into advanced formulation development, integrating an end-to-end platform. It boosts CDMO services and leverages API expertise for global market access and strategic asset out-licensing.
Alivus Life Sciences' board approved acquiring a 76% stake in IQGEN-X Pharma for ~₹9.12 Cr cash. This expands Alivus's offerings in the API & CDMO space, providing end-to-end solutions. IQGEN-X specializes in pharmaceutical formulation development and reported FY26 turnover of ₹3.48 Cr.